SRR614515
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- KRAS_SIGNALING_DN+0.415
- MYOGENESIS+0.367
- INFLAMMATORY_RESPONSE+0.348
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.335
- COAGULATION+0.301
- KRAS_SIGNALING_UP+0.238
- ALLOGRAFT_REJECTION+0.223
- SPERMATOGENESIS+0.208
- ESTROGEN_RESPONSE_LATE+0.174
Top 10 suppressed
- DNA_REPAIR-0.519
- MYC_TARGETS_V1-0.504
- UNFOLDED_PROTEIN_RESPONSE-0.483
- PROTEIN_SECRETION-0.473
- MYC_TARGETS_V2-0.471
- WNT_BETA_CATENIN_SIGNALING-0.451
- CHOLESTEROL_HOMEOSTASIS-0.398
- OXIDATIVE_PHOSPHORYLATION-0.385
- MITOTIC_SPINDLE-0.343
- E2F_TARGETS-0.341
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR602839 | GTEX | — | 0.949 |
| 2 | SRR1335064 | GTEX | — | 0.948 |
| 3 | SRR1366961 | GTEX | — | 0.945 |
| 4 | SRR659472 | GTEX | — | 0.932 |
| 5 | SRR1418604 | GTEX | — | 0.930 |
| 6 | SRR1444479 | GTEX | — | 0.927 |
| 7 | SRR1432765 | GTEX | — | 0.927 |
| 8 | SRR1459423 | GTEX | — | 0.927 |
| 9 | SRR1440962 | GTEX | — | 0.926 |
| 10 | SRR934982 | — | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.415 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.367 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.348 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.335 | Inavolisib | — uncovered |
| COAGULATION | 0.301 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.238 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.223 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.208 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.174 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.168 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.144 | Inavolisib | — uncovered |
| COMPLEMENT | 0.101 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.095 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.091 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.087 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.082 | Inavolisib | — uncovered |
| APOPTOSIS | 0.073 | Idelalisib | — uncovered |